ArticleCancers2021

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.

Francesca Romana Mauro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.